Positive Phase 1 safety/PK data and clear path to Phase 2 field study in 1H 2027 de-risk TNX-4800. With ~$185.5M cash and no debt, Tonix is well-funded through this catalyst. Monitor for FDA feedback on Phase 2 design (Type C meeting scheduled) and GMP manufacturing progress in 3Q 2026.
Price Chart
Executive Summary
Tonix Pharmaceuticals presented Phase 1 data for TNX-4800, a long-acting monoclonal antibody to prevent Lyme disease, at the Global Lyme Alliance. The Phase 1 study (N=44) showed TNX-4800 was safe and well-tolerated with a mean half-life of 62-69 days and dose-proportional PK. Pharmacokinetic simulations support a two-dose 350mg SC regimen maintaining serum levels above the 10 µg/mL MEC for 196 days, supporting the planned adaptive Phase 2 field study in 1H 2027. The company also reported ~$185.5M cash as of March 31, 2026, with no debt.
Key Facts
- Phase 1 trial (N=44) showed TNX-4800 safe and well-tolerated with no treatment-related SAEs and predominately mild AEs
- Mean half-life of TNX-4800 ranged from 62-69 days across dose groups
- PK simulations predict a two-dose 350mg SC regimen maintains serum levels above 10 µg/mL MEC for 196 days, supporting 6-month protection
- Planned adaptive Phase 2 field study in 1H 2027, pending FDA agreement
- Company had ~$185.5M cash as of March 31, 2026, with no debt
- TNX-4800 is a human anti-OspA monoclonal antibody with engineered Fc domain for extended half-life, licensed from UMass Chan Medical School in 2025
Financial Impact
No revenue or earnings impact; ~$185.5M cash position supports development through Phase 2
Risk Factors
- Phase 2 field study requires FDA agreement and faces enrollment/execution risk in Lyme-endemic areas
- TNX-4800 is still investigational; no guarantee of regulatory approval or commercial success
- Competition from OspA vaccines and other prophylactic mAbs in development
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001999371-26-010790 |
| Document: tnxp-8k_051526.htm | 0001999371-26-010790 |
| Document: 0001999371-26-010790-index-headers.html | 0001999371-26-010790 |
| Document: 0001999371-26-010790-index.html | 0001999371-26-010790 |
| Document: 0001999371-26-010790.txt | 0001999371-26-010790 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 8d ago | Press Release | $5.73 | awaiting T+20 | — | $5.30 (−7.50%) |
Oct 15, 2026 12d ago | 8-K | $6.42 | awaiting T+20 | — | $5.30 (−17.45%) |
Oct 2, 2026 24d ago | 8-K | $8.07 | awaiting T+20 | — | $5.30 (+34.32%) |
Sep 22, 2026 5w ago | 8-K | $10.59 $5.78 | ▼ −45.42% | ▼ −44.86% | $5.30 (−49.95%) |
Sep 8, 2026 7w ago | 8-K | $13.16 $7.70 | ▼ −41.49% | ▼ −43.46% | $5.30 (−59.73%) |
Aug 10, 2026 11w ago | 8-K | $12.59 $13.16 | ▲ +4.53% | ▲ +5.44% | $5.30 (−57.90%) |
Aug 10, 2026 11w ago | Press Release | $12.59 $13.16 | ▲ +4.53% | ▲ +5.44% | $5.30 (−57.90%) |
Aug 3, 2026 12w ago | 8-K | $10.67 $14.10 | ▲ +32.15% | ▲ +30.91% | $5.30 (−50.33%) |
Jul 27, 2026 13w ago | Press Release | $10.37 $12.45 | ▲ +20.06% | ▲ +16.76% | $5.30 (−48.89%) |
Jul 13, 2026 15w ago | 8-K | $11.71 $12.59 | ▲ +7.56% | ▲ +4.38% | $5.30 (−54.72%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers